Micron Biomedical Scales Production to Replace Needles
The company taps a new executive to shift its dissolvable microarray technology from research toward commercial production.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Do you believe self-administered drug technologies will make healthcare more accessible for your household?
Micron Biomedical has appointed Anand Subramony as Executive Vice President of Global Product Development and Combination Product Commercialization. The company is currently transitioning its needle-free, dissolvable microarray drug delivery platform from research toward commercial production.
Why it matters
Micron Biomedical is scaling operations to address logistical barriers in medicine, including cold chain requirements and medical waste. The leadership addition signals a strategic shift toward mass-producing therapies that eliminate traditional needle usage.
The company leverages a dissolvable microarray technology that bypasses traditional injection mechanisms, with 35 peer-reviewed publications validating its foundational research. Its Alpharetta facility serves as the current hub for scaling these arrays for small molecules, peptides, and vaccines.
The players
Micron Biomedical
A developer of needle-free drug delivery systems using proprietary dissolvable microarray technology to replace standard injections.
Anand Subramony
An executive with 27 years of experience in drug-device development, including previous roles at Eli Lilly, AstraZeneca, and Johnson & Johnson's ALZA Corporation.
The details
The technology utilizes microscopic arrays that dissolve upon contact with the skin, eliminating the need for sharps and specialized clinical disposal. By removing the requirement for refrigeration, known as the cold chain, this approach simplifies the global transport of sensitive biologics. Subramony will lead the transition of these proprietary arrays into market-ready combination products, which integrate the delivery device directly with the therapeutic agent.
Timeline
2014-2017: Anand Subramony directed the device development group at AstraZeneca.
2026: Micron Biomedical opened a commercial-scale manufacturing plant in Alpharetta.
October 28, 2026: The company announced the executive appointment of Anand Subramony.
The Tech Race
Micron Biomedical's efforts to scale microarray production follow a broader industry trend of decentralizing drug delivery to remove reliance on the cold chain. The firm aims to compete with established injectable standards by reducing the logistical overhead required for global therapeutic distribution.
Local residents and patients may eventually see reduced reliance on clinical appointments for vaccinations if these needle-free arrays reach the commercial market. The company's expansion in Alpharetta marks the infrastructure-building phase, though retail availability for these therapies remains to be determined.
The takeaway
Micron Biomedical is aggressively pivoting from a research-focused entity toward a commercial-scale manufacturer of needle-free delivery devices. Investors and industry stakeholders should monitor the deployment of new manufacturing lines across the United States over the next 36 months.
What happens next
Micron Biomedical plans to add additional manufacturing lines in the United States over the next three years to meet expected commercial demand.
Further reading
Learn more about the latest innovations in Biotech to see how local facilities are shaping global drug delivery.
More information
Review the company's progress and technology specifications on the Micron Biomedical company information website.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe self-administered drug technologies will make healthcare more accessible for your household?
